Azar points to Amgen, Merck and Gilead as evidence of progress in curbing drug prices
Amgen, as well as Merck and Gilead, are among examples the Trump administration pointed to of companies that have cut list prices on certain drugs. (Amgen)
Despite a slew of recent drug price hikes, the Trump administration claims it's seeing signs of progress in its efforts to curb the price of prescriptions.
Since May, when the president first announced his drug pricing blueprint, drug companies took 57% fewer price increases on brand-name drugs compared with the same period in 2017, Health and Human Services Secretary Alex Azar said on Tuesday.
“Some companies, such as Amgen, Merck, and Gilead, have cut the list price on certain drugs, and early data suggests that the 2019 price increases have been smaller and fewer in number than we saw in 2018," Azar told the Council for Affordable Health Coverage at an event in D.C. on Tuesday. “But drug companies have a lot further to go."
Free Daily Newsletter
Like this story? Subscribe to FierceHealthcare!
The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.